Quantcast

Susan G. Komen® Study Confirms Treatment Options for HER2-negative Patients With BRCA1/2 Mutations

Results of INFORM Study Released at San Antonio Breast Cancer Symposium

SAN ANTONIO–(BUSINESS WIRE)–Susan G. Komen®, the world’s leading breast cancer organization, today welcomed the results of the INFORM trial that were announced at the 2019 San Antonio Breast Cancer Symposium. The Komen-funded INFORM trial led by Dr. Nadine Tung shows that HER2-negative patients with a BRCA1/2 gene mutation have multiple effective treatment options.


Dr. Tung and colleagues sought to determine if cisplatin chemotherapy is a more effective treatment than the current, standard of care treatment, chemotherapy with doxorubicin and cyclophosphamide (commonly referred to as “AC”). Prior retrospective studies, which looked at treatment that has already occurred as part of the study, had indicated that cisplatin chemotherapy might work better than AC. The INFORM clinical trial was the first prospective study, or a study that evaluates treatment moving forward, to actually test this idea.

“For HER2-negative breast cancer patients with BRCA1/2 mutations, the INFORM trial confirmed that cisplatin chemotherapy is not more effective than standard chemotherapy with doxorubicin and cyclophosphamide. The results suggest that BRCA carriers may respond to both types of chemotherapy – which kill cancer cells by damaging DNA – giving them multiple options to treat their cancer,” said Dr. Tung. Prospective studies are essential for improving clinical practice.

She added, “Funding from Susan G. Komen was essential for this work.” Funded in part by a Komen Opportunity Grant, the INFORM trial is also part of the Translational Breast Cancer Research Consortium (TBCRC), which has been supported by Komen for more than 10 years.

Victoria Wolodzko, senior vice president of Mission at Susan G. Komen, added, “Patients with BRCA mutations face many challenges, especially those in rural or underserved areas. This work confirms that physicians have more options for these patients. Patients won’t need to wait for a specific treatment to ensure they are getting the best care no matter where they live.”

About Susan G. Komen®

Susan G. Komen® is the world’s leading nonprofit breast cancer organization, working to save lives and end breast cancer forever. Komen has an unmatched, comprehensive 360-degree approach to fighting this disease across all fronts and supporting millions of people in the U.S. and in countries worldwide. We advocate for patients, drive research breakthroughs, improve access to high-quality care, offer direct patient support and empower people with trustworthy information. Founded by Nancy G. Brinker, who promised her sister, Susan G. Komen, that she would end the disease that claimed Suzy’s life, Komen remains committed to supporting those affected by breast cancer today, while tirelessly searching for tomorrow’s cures.

Contacts

Sean Tuffnell

Susan G. Komen®

972-855-4382

[email protected]

Read the full article

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.